High-resolution cryo-EM structure of integrin αIIbβ3 bound to disease-causing maternal HPA-1a antibody that blocks integrin activation
Science Advances · 2026-07-17 · 12 (29)
DOI: 10.1126/sciadv.aed9833 ↗At a glance
Journal article in Science Advances, published on 2026-07-17. Written by José M de Pereda and 9 co-authors. Institution: Centro de Investigación del Cáncer. Instituto de Biología Molecular y Celular del Cáncer (IBMCC), Consejo Superior de Investigaciones Científicas (CS…. Major MEDLINE topics: Cryoelectron Microscopy, Platelet Glycoprotein GPIIb-IIIa Complex, Antigens, Human Platelet. 68 references. The full text is freely available in PubMed Central. Funded by: Landsteiner Foundation for Blood Transfusion Research, European Regional Development Fund, Instruct-ERIC.
Abstract (original language)
Integrins promote immunity, embryonic development, wound healing, and hemostasis, and are activated by ‘bent/closed’ to ‘extended/open’ conformational changes. Integrin αIIbβ3, being crucial for platelet activation and aggregation, is a therapeutic target for bleeding disorders and thrombosis. Human Platelet Antigen-1a (HPA-1a) on β3 is recognized by pregnancy-associated maternal alloantibodies, potentially causing fetal/neonatal alloimmune thrombocytopenia (FNAIT) and even intracranial hemorrhage or perinatal death. We report the structure of an anti-HPA-1a antibody fragment (Fab 26.4) in complex with integrin αIIbβ3 at high resolution by cryo–electron microscopy. Fab 26.4 binding locks αIIbβ3 in the inactive, bent/closed conformation, is incompatible with integrin extension, and inhibits αIIbβ3-dependent fibrinogen binding and platelet aggregation. Thus, anti-HPA-1a antibodies directly impair integrin activation by preventing required conformational changes. These insights will improve FNAIT diagnostics and treatment, and spark the development of novel allosteric inhibitors against β3 integrins for future therapeutic applications.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Centro de Investigación del Cáncer. Instituto de Biología Molecular y Celular del Cáncer (IBMCC), Consejo Superior de Investigaciones Científicas (CSIC), Universidad de Salamanca, 37007 Salamanca, Spain.
- Cell Adhesion and Migration Laboratory, Development and Disease theme, Institute of Biology, Gorlaeus Laboratory, Leiden University, 2333 CC, Leiden, The Netherlands.
- Centro Nacional de Biotecnología (CNB), CSIC, 28049, Madrid, Spain.
- Cryo-EM Facility. Department of Macromolecular Structures, CNB-CSIC, Universidad Autónoma de Madrid, c/ Darwin 3, 28049 Cantoblanco, Madrid, Spain.
- Université Grenoble Alpes, CNRS, CEA, EMBL, ISBG; F-38000 Grenoble, France.
- Sanquin Research and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
ORCID profiles: José M de Pereda, Wendy Stam, Marcos Gragera, Francisco J Chichón, Eleftherios Zarkadas, Ellen van der Schoot, Gestur Vidarsson, Junichi Takagi, Coert Margadant
Funding
- Landsteiner Foundation for Blood Transfusion Research
- European Regional Development Fund
- Instruct-ERIC
Cite
APA
de Pereda, J. M., Stam, W., Gragera, M., van der Meer, F., Chichón, F. J., Zarkadas, E., van der Schoot, E., Vidarsson, G., Takagi, J., & Margadant, C. (2026). High-resolution cryo-EM structure of integrin αIIbβ3 bound to disease-causing maternal HPA-1a antibody that blocks integrin activation. Science Advances, 12(29). https://doi.org/10.1126/sciadv.aed9833
Vancouver
de Pereda JM, Stam W, Gragera M, van der Meer F, Chichón FJ, Zarkadas E, et al. High-resolution cryo-EM structure of integrin αIIbβ3 bound to disease-causing maternal HPA-1a antibody that blocks integrin activation. Science Advances. 2026;12(29). doi:10.1126/sciadv.aed9833
BibTeX
@article{dePereda2026,
author = {de Pereda, José M and Stam, Wendy and Gragera, Marcos and van der Meer, Femke and Chichón, Francisco J and Zarkadas, Eleftherios and van der Schoot, Ellen and Vidarsson, Gestur and Takagi, Junichi and Margadant, Coert},
title = {High-resolution cryo-EM structure of integrin αIIbβ3 bound to disease-causing maternal HPA-1a antibody that blocks integrin activation},
journal = {Science Advances},
year = {2026},
volume = {12},
number = {29},
doi = {10.1126/sciadv.aed9833}
}
EUVIMED